SpringWorks Therapeutics, Inc.
SWTXNASDAQHealthcare
$46.99
+$0.01(+0.02%)
Market Cap$3.5B
P/E Ratio—
52W High$62
52W Low$28.21
SpringWorks Therapeutics, Inc. (SWTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
SWTX · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 6, 2025EPS Actual
-$0.54
Est. -$0.81 · +33.3%
Revenue
—
Est. $0.07B
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 6, 2025
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
SWTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.03
Rev. $1.54B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.03
Rev. Est.$1.54B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Aug 6, 2025 | -$0.81 | -$0.54 | +33.3% | — | $0.07B | — |
| ▼ Q2 FY2025 | May 9, 2025 | -$0.81 | -$1.11 | -37.0% | $0.05B | $0.07B | -26.7% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -$0.72 | -$1.04 | -44.4% | $0.06B | $0.07B | -7.7% |
| ▲ Q4 FY2024 | Nov 12, 2024 | -$0.76 | -$0.72 | +5.3% | $0.05B | $0.06B | -13.7% |
| ▲ Q3 FY2024 | Aug 7, 2024 | -$1.12 | -$0.54 | +51.8% | $0.06B | $0.03B | +74.0% |
| — Q2 FY2024 | May 2, 2024 | -$1.17 | -$1.18 | -0.8% | $0.02B | $0.01B | +72.0% |
| ▼ Q1 FY2024 | Feb 27, 2024 | -$1.25 | -$1.44 | -15.2% | $0.01B | $0.00B | +467.4% |
| ▲ Q4 FY2023 | Nov 2, 2023 | -$1.31 | -$1.27 | +3.0% | $0.01B | $0.00B | +179.3% |
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$0.54
EPS Est.
-$0.81
EPS Surpr.
+33.3%
Revenue
—
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$1.11
EPS Est.
-$0.81
EPS Surpr.
-37.0%
Revenue
$0.05B
Q1 FY2025
Feb 20, 2025Miss
EPS Actual
-$1.04
EPS Est.
-$0.72
EPS Surpr.
-44.4%
Revenue
$0.06B
Q4 FY2024
Nov 12, 2024Beat
EPS Actual
-$0.72
EPS Est.
-$0.76
EPS Surpr.
+5.3%
Revenue
$0.05B
Q3 FY2024
Aug 7, 2024Beat
EPS Actual
-$0.54
EPS Est.
-$1.12
EPS Surpr.
+51.8%
Revenue
$0.06B
Q2 FY2024
May 2, 2024
EPS Actual
-$1.18
EPS Est.
-$1.17
EPS Surpr.
-0.8%
Revenue
$0.02B
Q1 FY2024
Feb 27, 2024Miss
EPS Actual
-$1.44
EPS Est.
-$1.25
EPS Surpr.
-15.2%
Revenue
$0.01B
Q4 FY2023
Nov 2, 2023Beat
EPS Actual
-$1.27
EPS Est.
-$1.31
EPS Surpr.
+3.0%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.16 | $0.16 | $0.16 | 1 |
| Q3 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q2 FY2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q1 FY2026 | $-0.41 | $-0.41 | $-0.41 | 1 |
| Q4 FY2025 | $-0.55 | $-0.55 | $-0.55 | 1 |
| Q3 FY2025 | $-0.71 | $-0.71 | $-0.71 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.2B | $0.2B | $0.2B | 3 |
| Q3 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
| Q2 FY2026 | $0.2B | $0.2B | $0.2B | 2 |
| Q1 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
| Q4 FY2025 | $0.1B | $0.1B | $0.1B | 2 |
| Q3 FY2025 | $0.1B | $0.1B | $0.1B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q3 FY2025 | Aug 6, 2025 | +33.3% | $46.99 | — | — |
| ▼ Q2 FY2025 | May 9, 2025 | -37.0% | $46.20 | $46.26 | +0.13% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -44.4% | $55.73 | $59.93 | +7.54% |
| ▲ Q4 FY2024 | Nov 12, 2024 | +5.3% | $33.52 | $33.10 | -1.25% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +51.8% | $33.22 | $33.93 | +2.14% |
| ▲ Q2 FY2024 | May 2, 2024 | -0.8% | $46.84 | $43.35 | -7.45% |
| ▼ Q1 FY2024 | Feb 27, 2024 | -15.2% | $48.48 | $52.07 | +7.41% |
| ▲ Q4 FY2023 | Nov 2, 2023 | +3.0% | $23.91 | $25.25 | +5.60% |
Q3 FY2025—
Report Date
Aug 6, 2025
EPS Beat/Miss
+33.3%
Price Before
$46.99
Price After
—
Q2 FY2025+0.13%
Report Date
May 9, 2025
EPS Beat/Miss
-37.0%
Price Before
$46.20
Price After
$46.26
Q1 FY2025+7.54%
Report Date
Feb 20, 2025
EPS Beat/Miss
-44.4%
Price Before
$55.73
Price After
$59.93
Q4 FY2024-1.25%
Report Date
Nov 12, 2024
EPS Beat/Miss
+5.3%
Price Before
$33.52
Price After
$33.10
Q3 FY2024+2.14%
Report Date
Aug 7, 2024
EPS Beat/Miss
+51.8%
Price Before
$33.22
Price After
$33.93
Q2 FY2024-7.45%
Report Date
May 2, 2024
EPS Beat/Miss
-0.8%
Price Before
$46.84
Price After
$43.35
Q1 FY2024+7.41%
Report Date
Feb 27, 2024
EPS Beat/Miss
-15.2%
Price Before
$48.48
Price After
$52.07
Q4 FY2023+5.60%
Report Date
Nov 2, 2023
EPS Beat/Miss
+3.0%
Price Before
$23.91
Price After
$25.25
Avg Beat Reaction-0.24%
Avg Miss Reaction+5.03%
Beat Rate5 / 8 quarters
Largest Move+7.54% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: SWTX ends December
SpringWorks Therapeutics, Inc. (SWTX) most recently reported earnings on August 6, 2025 for Q3 FY2025, posting EPS of $-0.54 — beating the analyst consensus of $-0.81 by +33.3%. The next SWTX earnings date is expected around September 1, 2026.
Each quarter, investors track SWTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. SWTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
SWTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
SWTX earnings · 5 questionsSpringWorks Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. SWTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; SWTX historically reports after market close (AMC).
SWTX earnings datewhen is SWTX earningsSWTX next earnings datewhen does SWTX report earningsSWTX earnings calendar
▸ Source: FMP · SpringWorks Therapeutics, Inc. SEC filings · US GAAP · SpringWorks Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026